Christoph Correll, MD: antipsychotics in children
Are Zyprexa, Risperdal, and Abilify overprescribed in children?
Update: June 11, 2012
Since our extensive coverage of the marketing strategies that led to wide misuse of antipsychotics, JNJ agreed to pay nearly $2.2 Billion in penalties to settle the DOJ investigation.
__________________________________________________________________________
January 12, 2010 By Steven Greer, MD
The antipsychotic drug market is one of the largest in the drug business. Zyprexa is Eli Lilly’s largest drug with an estimated $4.6 B (USD) in revenue for 2009 (Barclays estimates). Bristol-Myers Squibb’s Abilify is an important drug to the company with estimated 2009 revenue of $2.4 B. The Risperdal franchise for JNJ, at $2.3 B, and AstraZeneca’s Seroquel, at more than $4 B, are also vital to the respective companies.
Accompanying this massive revenue stream is one of the most powerful marketing and lobbying strategies in the world resulting in several million Americans now taking antipsychotics. Is classic schizophrenia with delusions and hallucinations really that prevalent or are these drugs being overprescribed in unapproved indications?
Evidence is growing that off-label prescribing of antipsychotics is leading to inappropriate usage of these drugs in the elderly nursing home setting and in the pediatric setting. More troubling, in the pediatric population, disadvantaged minority children are far more likely to be prescribed these drugs, leading to a lifelong sequelae of disease.
Pediatric psychiatrist. Dr. Correll, discusses whether drugs like Abilify, Zyprexa, Risperdal, Fanapt, Seoul, etc are overprescribed.
Recent studies have added to the literature showing the severe adverse events caused by antipsychotics (weight gain, diabetes, elevated lipids, suicide, etc.). In our previous story (below), Dr. Correll detailed the metabolic syndrome that arises rapidly in children on antipsychotics.
Antipsychotics in children associated with significant weight gain and elevated lipids
The use of antipsychotics in children is controversial for many reasons. The data to support this practice is scant and biased by industry funding. The U.S. Senate has documented this at length. Data are now mounting that show antipsychotics create significant adverse events, including large weight gain and elevated cholesterol, or “metabolic syndrome” in many cases. Given the ages of the children, these adverse events are harmful to development and may shorten lifespan.
Christoph Correll, MD, pediatric psychiatrist and recent author of a white paper in JAMA on this topic, discusses the adverse events in children associated with antipsychotic usage.
Topics discussed:
- Is Abilify unique in not causing weight gain?
- Which drugs caused the most weight gain and elevated lipid levels?
JAMA, North Shore LIJ, Psychiatry | apples49 | 
July 18, 2012 11:37 am
No Comments
No comments yet.
Notice: comments_rss_link is deprecated since version 2.5! Use post_comments_feed_link() instead. in /data/30/1/121/80/1121895/user/1185656/htdocs/wordpress/wp-includes/functions.php on line 3406
RSS feed for comments on this post.
TrackBack URI
